Trial Condition(s):
Early signs of efficacy study with Riociguat in adult homozygous delta F508 Cystic Fibrosis patients
17020
Not Available
Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
- Signed informed consent available before any study specific tests or procedures are performed - Patients must be at least 18 years of age at time of inclusion (i.e. upon signature of informed consent) - Patient diagnosed with Cystic Fibrosis according to standard criteria (i.e. either elevated sweat chloride content above 60 mmol/ L and/ or genetic testing) - Patient is homozygous for the deltaF508 mutation - Patient has a mild-to-moderate stage of lung disease as determined by FEV1 (FEV1 between 40 and 100% predicted) - Patient has a stable condition of lung disease (no ongoing or recent pulmonary exacerbation and no change in current treatment) within the last 4 weeks prior to screening - Ability and willingness to understand and follow study procedures for the entire study - Patients do not smoke. Patients with a history of smoking can be included, if they have refrained from smoking for the last 3 months. If a patients starts smoking during the study participation, he/ she needs to be excluded and considered to be a drop out - Body mass index (BMI): ≥ 16 kg/ m² (calculated by dividing the patient’s weight by the square of his/ her height [kg/ m2]) Inclusion criterion valid for study part 1 only: - Women of childbearing potential must agree to use adequate contraception when sexually active. 'Adequate contraception' is defined as one highly effective form of contraception (intrauterine devices [IUD], contraceptive implants or tubal sterilization) or a combination of methods (hormone method with a barrier method ). If a partner's vasectomy is the chosen method of contraception or if a partner has documented azoospermia, a hormone or barrier method must be used in combination. Adequate contraception is required from the signing of the informed consent form up until 4 weeks after the last study drug administration Inclusion criteria valid for study part 2 only: - Women of childbearing potential must agree to use adequate contraception when sexually active. ‘Adequate contraception’ is defined as one highly effective form of contraception (intrauterine devices [IUD], contraceptive implants or tubal sterilization) or a combination of methods (hormone method with a barrier method). For patients on Orkambi hormonal methods (including hormonal oral contraceptives) cannot be accepted in this study. They need to choose non-hormonal methods. If a partner’s vasectomy is the chosen method of contraception or if a partner has documented azoospermia, a hormone or barrier method must be used in combination. Adequate contraception is required from the signing of the informed consent form up until 4 weeks after the last study drug administration - Patients receiving Orkambi (Lumcaftor + Ivacaftor) as part of their standard care need to be on stable Orkambi treatment for at least 3 months prior to screening (patients on Lumacaftor and/or Ivacaftor are excluded in part 1)
- Patients with Cystic Fibrosis with any background other than homozygous deltaF508 mutation - Exclusion criterion only valid for study part 1: Patients receiving treatment with Lumacaftor and/ or Ivacaftor - Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization. Also any history of moderate hemoptysis within the 3 months prior to inclusion - Any history of pneumothorax, bronchial artery embolization or massive hemoptysis. Massive hemoptysis being defined as acute bleeding >240 mL in a 24-hour period or recurrent bleeding >100 mL/ d over several days - A positive sputum culture for Burkholderia cenocepacia, Burkholderia dolosa, and/ or Mycobacterium abscessus either currently or within the previous year - Active allergic broncho-pulmonary aspergillosis - Current pulmonary exacerbation - Known history of solid organ transplantation - Known history of any form of pulmonary hypertension - Clinically relevant deviations of the screened laboratory parameters from reference ranges outside of expected changes for Cystic Fibrosis patients, especially a hemoglobin value below 110 g/L or a creatinine clearance based on the Cockcroft-Gault formula < 15 ml/ min
Locations | |
---|---|
Locations Investigative Site Toronto, Canada, M5B 1W8 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site Berlin, Germany, 13353 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site London, United Kingdom, SW3 6NP | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site Belfast, United Kingdom, BT12 7AB | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site Birmingham, United States, 35233-1711 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site Saint Louis, United States, 63110 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site Denver, United States, 80206 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site PARIS, France, 75674 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site ROTTERDAM, Netherlands, 3015 CE | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Locations Investigative Site BRUXELLES - BRUSSEL, Belgium, 1090 | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Multi-center phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
2